Picture of Aoti logo

AOTI Aoti News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

REG - AOTI, Inc. - Director/PDMR Shareholding

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250502:nRSB2649Ha&default-theme=true

RNS Number : 2649H  AOTI, Inc.  02 May 2025

2 May 2025

 

AOTI Inc.

(the "Company")

 

Director/PDMR Shareholding - transfer of shares to SIPP

 

The Company was informed on 1 May 2025 that Mr Douglas Lefort, Non-executive
Chaiman of the Company and his spouse, transferred a total of 149,895 common
shares of $0.00001 each in the capital of the Company ("Common Shares") into
their Self-Invested Personal Pensions ("SIPPs") from their jointly owned
consulting vehicle, Wolfpack Consulting Limited.  This was effected by the
purchase and sale of 74,948 Common Shares at 80 pence each on 1 May 2025 by Mr
Lefort and the purchase and sale of 74,947 Common Shares at 80 pence each on 1
May 2025 by Mrs Lefort.

 

Following the purchase and sale transactions, there is no change to Mr
Lefort's beneficial holding (including that of his spouse) and the total
interest in the Company remains the same at 1,451,621 Common Shares,
representing approximately 1.36% of the Company's issued share capital.

 

The below notification, made in accordance with Article 19 of the Market Abuse
Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with
them

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1.   Mr Douglas Lefort

                                                                   2.   Mrs Gillian Lefort
 2    Reason for the notification

 a)   Position/status                                              1.   Non-executive Chairman

                                                                   2.   PCA of Douglas Lefort
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AOTI Inc.

 b)   LEI                                                          213800ZGCNDSTWIRK687

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common shares of $0.00001 each

      Identification code

                                                                   ISIN: US03690C1027
 b)   Nature of the transaction                                    1. Purchase of Common Shares into Mr Lefort's SIPP on 1 May 2025

                                                                   2. Sale of Common Shares by Mr Lefort on 1 May 2025

                                                                   3. Purchase of Common Shares into Mrs Lefort's SIPP on 1 May 2025

                                                                   4. Sale of Common Shares by Mrs Lefort on 1 May 2025

 c)   Price(s) and volume(s)                                       Price(s)      Volume(s)

                                                                 1.    80p     74,948
                                                                   2.    80p     74,948
                                                                   3.    80p     74,947
                                                                   4.    80p     74,947
 d)   Aggregated information

      - Aggregated volume                                          149,895

      - Price                                                      80p

 e)   Date of the transaction                                      1 May 2025

 f)   Place of the transaction                                     London Stock Exchange

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

149,895

 

80p

e)

 

Date of the transaction

 

1 May 2025

f)

 

Place of the transaction

 

London Stock Exchange

 

For further information please contact:

 

 AOTI, INC.                                                    +44 (0)20 3727 1000

 Dr. Mike Griffiths, Chief Executive Officer & President       ir@aotinc.net (mailto:ir@aotinc.net)

 Jayesh Pankhania, Chief Financial Officer
                                                                +44 (0)20 7418 8900

 Peel Hunt LLP (Nominated Adviser and Broker)

 Dr. Christopher Golden, James Steel
 FTI Consulting (Financial PR & IR)                             +44 (0)20 3727 1000

 Simon Conway, Alex Davis                                      AOTI@fticonsulting.com (mailto:AdvancedOxygenTherapy@fticonsulting.com)

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO2®) Therapy has demonstrated
in differentiating, robust, double-blinded randomised controlled trials (RCT)
and real-world evidence (RWE) studies to more-durably reduce the recurrence of
Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent
reduction in hospitalisations and 71 per cent reduction in amputations over 12
months. TWO2® Therapy can be administered by the patient at home, improving
access to care and enhancing treatment compliance. TWO2® Therapy has received
regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health
Canada, the Chinese National Medical Products Administration, Australia (TGA)
and in Saudi Arabia. Also see www.aotinc.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBGGDUXBGDGUD

Recent news on Aoti

See all news